LL-37

LL-37 is the sole human member of the cathelicidin family of antimicrobial peptides, derived from the C-terminal fragment of the human cationic antimicrobial protein 18 (hCAP18). This 37-amino acid peptide was identified in the 1990s as a critical component of human innate immunity. LL-37 functions through multiple mechanisms including direct antimicrobial activity via membrane disruption, immunomodulation through regulation of inflammatory responses, chemotaxis of immune cells, lipopolysaccharide neutralization, and promotion of wound healing and angiogenesis. The peptide is expressed in epithelial tissues of the skin, gastrointestinal tract, respiratory tract, and in various leukocytes including neutrophils, monocytes, and lymphocytes. Its expression is regulated by vitamin D, bacterial components, cytokines, and tissue injury signals. Currently, LL-37 is not FDA-approved for therapeutic use and remains available only for research purposes, though phase 1 clinical trials have been completed for melanoma and exploratory studies conducted for COVID-19 and sepsis.

Antimicrobial Activity

• Broad-spectrum pathogen defense: LL-37 exhibits potent antimicrobial effects against both Gram-positive and Gram-negative bacteria, fungi including Candida auris, and certain viruses through membrane disruption mechanisms ^[1][2][6]
• Anti-biofilm properties: Demonstrates effectiveness against biofilm-forming pathogens, which are notoriously resistant to conventional antibiotics, making it valuable for treating chronic infections ^[5]
• LPS neutralization: Binds and neutralizes bacterial lipopolysaccharide, protecting against endotoxemia and septic shock ^[1][3]

Immune Modulation

• Inflammatory regulation: Modulates immune responses by suppressing excessive inflammation while enhancing protective immunity, including inhibition of macrophage pyroptosis in sepsis ^[3][4]
• Chemotactic effects: Recruits neutrophils, monocytes, and T cells to sites of infection or injury, coordinating adaptive immune responses ^[2]
• Dendritic cell enhancement: Boosts dendritic cell performance for cancer immunotherapy by increasing tumor-specific CD8+ T cell production and reducing immune checkpoint expression ^[12]

Tissue Repair and Regeneration

• Wound healing promotion: Accelerates re-epithelialization, granulation tissue formation, and collagen organization in injured tissues ^[5][10]
• Angiogenesis induction: Stimulates new blood vessel formation through PGE2-EP3 signaling and FPRL1 activation, critical for tissue repair and ischemic conditions ^[10][11]
• Epithelial barrier integrity: Promotes epithelial cell proliferation and migration, maintaining barrier function in skin and mucosal surfaces ^[2]

Clinical Safety Profile

LL-37 has demonstrated a generally favorable safety profile in limited human studies. A small-scale exploratory trial in COVID-19 patients (n=11) reported no discomfort or adverse events during oral administration. A phase 1 clinical trial using intratumoral injections for melanoma patients with cutaneous metastases was completed without major safety concerns. However, dermatologic toxicity has been observed in some melanoma patients receiving novel LL-37 therapy, requiring detailed clinicopathologic examination. The peptide's safety in long-term use remains inadequately characterized due to the limited scope and duration of existing studies.

Regulatory Status

LL-37 is not FDA-approved for therapeutic use in humans and has not received regulatory approval from any major health authority as a peptide antibiotic. The peptide exists in a regulatory gray zone where it can be legally purchased for research purposes only in the United States and many other countries. It is not classified as a controlled substance but cannot be marketed for human therapeutic applications without appropriate regulatory clearance.

Side Effects and Risks

• Local reactions: Topical or intralesional administration may cause localized irritation, inflammation, or dermatologic toxicity
• Cytotoxicity concerns: High concentrations can damage human cells, necessitating careful dose optimization
• Proteolytic degradation: Susceptibility to protease degradation in physiological environments may reduce bioavailability and efficacy
• Context-dependent effects: LL-37 shows dual roles in certain conditions; while beneficial in some contexts, it may promote fungal growth (e.g., Aspergillus fumigatus) or exacerbate inflammatory skin diseases like psoriasis when dysregulated

Research Gaps

Comprehensive long-term safety data in humans is lacking. Clinical translation faces challenges including high production costs, poor bioavailability, potential toxicity at therapeutic concentrations, and limited pharmacokinetic/pharmacodynamic profiles. Optimal dosing regimens, delivery methods, and patient selection criteria require extensive investigation before clinical deployment.